AtriCure, Inc. (ATRC) Shares Sold by DAFNA Capital Management LLC
DAFNA Capital Management LLC trimmed its stake in AtriCure, Inc. (NASDAQ:ATRC) by 24.2% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 384,145 shares of the medical device company’s stock after selling 122,801 shares during the quarter. AtriCure makes up 6.6% of DAFNA Capital Management LLC’s holdings, making the stock its 2nd largest holding. DAFNA Capital Management LLC owned about 1.12% of AtriCure worth $9,316,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors also recently modified their holdings of the company. US Bancorp DE grew its holdings in shares of AtriCure by 152.1% in the 2nd quarter. US Bancorp DE now owns 4,202 shares of the medical device company’s stock worth $102,000 after acquiring an additional 2,535 shares during the last quarter. Sei Investments Co. grew its holdings in shares of AtriCure by 75.5% in the 2nd quarter. Sei Investments Co. now owns 6,933 shares of the medical device company’s stock worth $168,000 after acquiring an additional 2,983 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of AtriCure by 3.8% in the 2nd quarter. Legal & General Group Plc now owns 8,528 shares of the medical device company’s stock worth $208,000 after acquiring an additional 312 shares during the last quarter. Tudor Investment Corp ET AL acquired a new position in shares of AtriCure in the 2nd quarter worth $253,000. Finally, Commerce Bank acquired a new position in shares of AtriCure in the 2nd quarter worth $266,000. Institutional investors and hedge funds own 82.11% of the company’s stock.
In related news, Director Elizabeth D. Krell sold 10,000 shares of the company’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $22.40, for a total value of $224,000.00. Following the completion of the sale, the director now owns 29,967 shares in the company, valued at approximately $671,260.80. The transaction was disclosed in a filing with the SEC, which is available through this link. 10.00% of the stock is owned by corporate insiders.
A number of equities analysts recently issued reports on the company. BidaskClub cut AtriCure from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Needham & Company LLC restated a “buy” rating and issued a $26.00 target price (up from $25.00) on shares of AtriCure in a report on Friday, July 28th. Zacks Investment Research upgraded AtriCure from a “sell” rating to a “hold” rating in a report on Monday. Leerink Swann restated an “outperform” rating and issued a $26.00 target price on shares of AtriCure in a report on Friday, June 16th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $25.00 price target on shares of AtriCure in a report on Sunday, July 30th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $24.83.
Shares of AtriCure, Inc. (ATRC) traded up 0.22% on Thursday, hitting $23.05. The stock had a trading volume of 35,035 shares. The company’s market capitalization is $791.40 million. AtriCure, Inc. has a one year low of $14.78 and a one year high of $25.18. The firm has a 50 day moving average price of $21.75 and a 200 day moving average price of $21.73.
AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Thursday, July 27th. The medical device company reported ($0.21) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.05. AtriCure had a negative net margin of 19.56% and a negative return on equity of 19.56%. The business had revenue of $45.23 million during the quarter, compared to analysts’ expectations of $44.15 million. During the same quarter in the prior year, the company earned ($0.26) EPS. The firm’s quarterly revenue was up 14.0% on a year-over-year basis. On average, equities research analysts predict that AtriCure, Inc. will post ($0.95) earnings per share for the current fiscal year.
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Stock Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related stocks with our FREE daily email newsletter.